Meiling Lai
First author of a 2026 study of immune aging across the canine lifespan and short-term responses to rapamycin.
Institute of Advanced Biotechnology & Institute of Homeostatic Medicine, Southern University of Science and Technology · Shenzhen, China
Meiling Lai is at the Institute of Advanced Biotechnology and Institute of Homeostatic Medicine at the Southern University of Science and Technology (SUSTech) in Shenzhen, China. In 2026 she led a study profiling immune aging across the canine lifespan and testing short-term geroprotective interventions — rapamycin, the SGLT2 inhibitor canagliflozin, and dietary restriction — in young Beagles, finding rapamycin produced the broadest shift in blood cytokines of the three.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | A | Sex-stratified immune patterns across the canine lifespan and short-term responses to geroprotective interventions LAI2026 Led the canine immune-aging study testing rapamycin, canagliflozin and dietary restriction. |
Co-authors in the Atlas
People with a profile here who share at least one study with Meiling Lai.
- Yu-Xuan Lyu Corresponding/senior author of the same 2026 canine immune-aging and geroprotective-intervention study.
Every researcher with a profile →
Thank you. Your answer was counted anonymously.
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.